TY - JOUR
T1 - Nivolumab and pembrolizumab
T2 - Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
AU - Prasad, Vinay
AU - Kaestner, Victoria
N1 - Publisher Copyright:
© 2017
PY - 2017/4
Y1 - 2017/4
N2 - Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer. In this review we will summarize the data for efficacy and toxicity for these two agents. We conclude that they represent two valuable but interchangeable alternatives to target their approved indications. We will discuss how this can help global payers seeking to contain the cost of cancer therapeutics that continues to spiral out of control.
AB - Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer. In this review we will summarize the data for efficacy and toxicity for these two agents. We conclude that they represent two valuable but interchangeable alternatives to target their approved indications. We will discuss how this can help global payers seeking to contain the cost of cancer therapeutics that continues to spiral out of control.
KW - Drug manufacturing
KW - Me-too drugs
KW - Nivolumab
KW - Pembrolizumab
UR - http://www.scopus.com/inward/record.url?scp=85028355340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028355340&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2017.06.007
DO - 10.1053/j.seminoncol.2017.06.007
M3 - Review article
C2 - 28923211
AN - SCOPUS:85028355340
SN - 0093-7754
VL - 44
SP - 132
EP - 135
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 2
ER -